June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

Study Tests New Clot Removal Access Route

A new clinical trial is investigating whether removing clots using a modified access point can better prevent post-thrombotic syndrome in patients with extensive deep vein thrombosis.

Conexiant

June 09, 2025

Dark Metabolome Debate: A Call for Context

Shuzhao Li sees no fundamental disagreement between “camps”

The Analytical Scientist

June 03, 2025

Plant Diet May Delay Myeloma Precursor Progression

First clinical trial shows high-fiber plant-based diet improves microbiome and may delay MGUS/SMM progression to multiple myeloma.

Conexiant

June 02, 2025

Restrictive Platelet Thresholds Endorsed in New Guidelines

International experts reviewed decades of data and endorsed lower platelet transfusion thresholds.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant